A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
Conditions
Friedreich Ataxia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UCLA Neurology, Los Angeles, California, United States
Contact: Principal Investigator (Susan Perlman)University of Colorado, Aurora, Colorado, United States
Contact: Principal Investigator (Trevor Hawkins)University of Florida, Gainesville, Florida, United States
Contact: Principal Investigator (Sub Subramony)Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Contact: Principal Investigator (David Lynch)Medizinische Universität Innsbruck, Innsbruck, Austria
Contact: Principal Investigator (Sylvia Boesch)HUB-Hôpital Erasme, Brussels, Belgium
Contact: Principal Investigator (Naeije Gilles)Center for hereditary ataxias, Motol, Motol, Prague, Czechia
Contact: Principal Investigator (Martin Vyhnalek)Universitätsklinikum Tübingen, Tübingen, Baden-Würtemberg, Germany
Contact: Principal Investigator (Ludger Schöls)University Hospital Aachen, Aachen, Germany
Contact: Principal Investigator (Kathrin Reetz)Klinikum der Universität München, Munich, Germany
Contact: Principal Investigator (Thomas Klopstock)Scientific Institute, IRCCS E. Medea, Conegliano, Italy
Contact: Principal Investigator (Gabriella Paparella)Fondazione I.R.C.C.S. Istituto Neurologico C. Besta, Milan, Italy
Contact: Principal Investigator (Caterina Mariotti)Ospedale Pediatrico Bambino Gesu, Rome, Italy
Contact: Principal Investigator (Gessica Vasco)Stichting Radboud universitair medisch centrum, Nijmegen, Netherlands
Contact: Principal Investigator (Bart van de Warrenburg)
Study leads
Medical Director
Study Director
Biogen